Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.46 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.42 |
| ▸ | CSF1R | P07333 | 1/20 | 0.42 |
| ▸ | ROR1 | Q01973 | 3/20 | 0.40 |
| ▸ | DDR1 | Q08345 | 7/20 | 0.40 |
| ▸ | ABL1 | P00519 | 5/20 | 0.40 |
| ▸ | KLK7 | P49862 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL588504 | 0.83 | MKNK1 (0.44) | MKNK1DYRK1ACSF1RROR1DDR1 | |
| SCHEMBL22369939 | 0.83 | MKNK1 (0.46) | MKNK1DYRK1ACSF1RROR1DDR1 | |
| SCHEMBL10207631 | 0.80 | MKNK1 (0.44) | MKNK1DYRK1ACSF1RROR1DDR1 | |
| SCHEMBL29890013 | 0.80 | MKNK1 (0.41) | MKNK1DYRK1ACSF1RROR1DDR1 | |
| SCHEMBL24496139 | 0.79 | MKNK1 (0.43) | MKNK1DYRK1ACSF1RROR1DDR1 | |
| SCHEMBL19840388 | 0.79 | MKNK1 (0.49) | MKNK1DYRK1AKLK7 | |
| SCHEMBL14705592 | 0.76 | CSF1R (0.55) | CSF1RROR1DDR1ABL1 | |
| SCHEMBL19866359 | 0.75 | MKNK1 (0.40) | MKNK1DYRK1ACSF1RROR1DDR1 | |
| SCHEMBL20159172 | 0.74 | MKNK1 (0.40) | MKNK1DYRK1ACSF1RROR1DDR1 | |
| SCHEMBL24885728 | 0.74 | ABL1 (0.46) | CSF1RROR1DDR1ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220389039-A1 | P2X3 AND/OR P2X2/3 RECEPTOR ANTAGONIST, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF | BEIJING TIDE PHARMACEUTICAL CO LTD (CN) | 2022-12-08 | — | — | US | disclosed |
| US-20220265669-A1 | COMPOUNDS USEFUL FOR INHIBITING RAF DIMERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-08-25 | — | — | US | disclosed |
| US-9029533-B2 | Substituted acetylenic imidazo[1,2-A]pyridazines as kinase inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2015-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220265669-A1 | COMPOUNDS USEFUL FOR INHIBITING RAF DIMERS | BRAF, RAF1, NRAS | MKNK1 700/4885DYRK1A 186/4885CSF1R 1224/4885 |
| US-20220389039-A1 | P2X3 AND/OR P2X2/3 RECEPTOR ANTAGONIST, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF | P2RX3, P2RX2, P2RX7 | MKNK1 3633/4885DYRK1A 2555/4885CSF1R 1142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.